Boryung Pharm succeeded in avoidance of ‘Alimta Inj’ patent
Over the hydrate patent(Korea Patent Registration No. 0744917) related to the main substance of the recent lung cancer treatment ‘Alimta(generic name: pemetrexed disodium heptahydrate),’ Boryung Pharm(President Tae-hong Choi) has won the defensive confirmation trial for the scope of the right aga...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
